AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16911289
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT) (160 mg g1)
Trial: 16911289
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT)
Trial: 12821233
Drug: Intravenous acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acetylcysteine (NAC) 150 mg/kg in 500 ml N/saline over 30 min immediately before contrast followed by 50 mg/kg in 500 ml N/saline over 4 h (n = 41)
Trial: 12821233
Drug: Intravenous hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydration (1 ml/kg/h N/saline for 12 h pre‐ and post‐contrast, n = 39)
Trial: 10913474
Drug: Abciximab plus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab plus heparin (70 U/kg)
Trial: 10913474
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (70 U/kg)
Trial: 1517792
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan (BU) 16 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Trial: 1517792
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Trial: 1517792
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 147 mg/kg
Trial: 1517792
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 174 mg/kg
Trial: 6471030
Drug: Influenza Vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza Vaccine A
Trial: 6471030
Drug: Influenza Vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza Vaccine B
Trial: 26641555
Drug: Interventions for
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions for patients naïve to depression screening, pneumococcal vaccination, inhaled control medications, or smoking cessation.
Trial: 20716817
Drug: tgAAC09 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tgAAC09 vaccine (3x10^9, 3x10^10, and 3x10^11 DNase resistant particles/ml)
Trial: 20716817
Drug: tgAAC09 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tgAAC09 vaccine (high dose)
Trial: 20716817
Drug: tgAAC09 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tgAAC09 vaccine (low and mid-dose)
Trial: 20716817
Drug: tgAAC09 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tgAAC09 vaccine
Trial: 17929487
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of a local anesthetic
Trial: 15546807
Drug: Lozenge containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge containing lavender oil, extracts from hops, lemon balm and oat
Trial: 15546807
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge without active ingredients
Trial: 10468903
Drug: MK-677 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 (25 mg/day; n = 12)
Trial: 7817022
Drug: Intravitreal amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, immediate vitrectomy
Trial: 7817022
Drug: Intravitreal amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, vitreous tap and treatment with or without intravenous antibiotics
Trial: 3178249
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical bufexamac
Trial: 22120857
Drug: Enalapril or
RxNorm normalized name: enalapril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril or Amlodipine without Atorvastatin
Trial: 15254494
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous serum application (20% diluted with physiological saline, applied four times a day for up to 12 weeks)
Trial: 15254494
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic and autologous serum
Trial: 15254494
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibiotic alone)
Trial: 15254494
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous serum application
Trial: 10598691
Drug: Dorzolamide-timolol combination
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily
Trial: 9787367
Drug: Dorzolamide (2%)
DrugBank: Dorzolamide (DB00869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dorzolamide (2%) three times daily and timolol (0.5%) twice daily
Trial: 10598691
Drug: Dorzolamide-timolol combination
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily during open-label extension
Trial: 7616872
Drug: Estradiol implants
RxNorm normalized name: Oestradiol Implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol implants 50 mg alone (E)
Trial: 7616872
Drug: Estradiol 50
RxNorm normalized name: estradiol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 50 mg plus testosterone 50 mg (E&T)
Trial: 2239120
Drug: Methohexital 80
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital 80 mg/ml, 20 mg/kg rectally, 15 min before transportation
Trial: 2239120
Drug: Pentobarbital 28
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbital 28 mg/ml, 7 mg/kg rectally, 45 min before transportation
Trial: 28681535
Drug: Treatment assignments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assignments (aspirin/clopidogrel vs aspirin/placebo)
Trial: 26220871
Drug: Telephone-based support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based support (weekly for 12 weeks, 15-25 min/week)
Trial: 23958393
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg per day)
Trial: 23958393
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl (60 mg per day)
Trial: 18985740
Drug: Aprepitant triple
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant triple therapy (125 mg p.o. on day 1, 80 mg on days 2 and 3, and 4 mg dexamethasone and ondansetron as specified)
Trial: 18985740
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (16 mg dexamethasone and ondansetron as specified)
Trial: 18985740
Drug: Aprepitant triple
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant triple therapy
Trial: 17097819
Drug: Alcoholic drinks
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic drinks (M=0.114 g% breath alcohol concentration [BrAC])
Trial: 2907877
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ofloxacin orally
Trial: 2907877
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ofloxacin orally
Trial: 2907877
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ofloxacin intravenously
Trial: 29515226
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (control)
Trial: 18157705
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (800 mg once-daily for 8 days)
Trial: 7752178
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 or 40 mg/day)
Trial: 2261364
Drug: Single course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single course of cytotoxic therapy
Trial: 2261364
Drug: Single course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single course of cytotoxic chemotherapy
Trial: 2261364
Drug: Prolonged adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged adjuvant therapy (6 or 7 courses)
Trial: 2261364
Drug: Prolonged cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged cytotoxic therapy
Trial: 2261364
Drug: Prolonged therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged therapy vs. one single course among node-positive patients
Trial: 29202767
Drug: Glycopyrrolate 25
RxNorm normalized name: GLYCOPYRROLATE 25MCG/ML INHL 2 VIAL PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 25 μg BID
Trial: 29202767
Drug: Glycopyrrolate 50
RxNorm normalized name: glycopyrrolate 500 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 50 μg BID
Trial: 21282425
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral dose of efavirenz
Trial: 16459222
Drug: Low glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glycemic index diet with 30 g of soy protein and 4 g of phytosterols per day (LGID)
Trial: 10919427
Drug: Low moisture‐conserving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low moisture‐conserving performance (Group L)
Trial: 8995494
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine (Navelbine) at 80 mg/m2 per week after ingestion of a standard meal
Trial: 8995494
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in fasting state
Trial: 8995494
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in two divided doses
Trial: 8995494
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral administration of vinorelbine in two divided doses
Trial: 1431363
Drug: CFPM 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFPM 2 g/day
Trial: 1431363
Drug: CFPM 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFPM 4 g/day
Trial: 1431363
Drug: CAZ 2
RxNorm normalized name: Avycaz 2.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAZ 2 g/day
Trial: 4051271
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intratracheal aerosolized etidocaine
Trial: 4051271
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg intratracheal aerosolized etidocaine
Trial: 21928099
Drug: GF Strong
RxNorm normalized name: Strongid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GF Strong Water Protocol (GFSWP) - oral water intake, independent or supervised access, safe swallowing strategies
Trial: 20039425
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 4 mg/kg or 8 mg/kg plus methotrexate (MTX)
Trial: 17667889
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IV thrombolytic therapy)
Trial: 17667889
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IV and IA thrombolysis
Trial: 11972576
Drug: Zolmitriptan orally
RxNorm normalized name: Zolmitriptan Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan orally disintegrating tablet 2.5 mg
Trial: 10102964
Drug: FCB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCB group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with tripotassium dicitrato bismuthate 240 mg b.d.)
Trial: 10102964
Drug: FCL group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCL group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with lansoprazole 30 mg daily)
Trial: 10102964
Drug: FCO group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with furazolidone 100 mg b.d.)
Trial: 10102964
Drug: MCO group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with metronidazole 400 mg b.d.)
Trial: 8547961
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tumor necrosis factor (TNF) and actinomycin D
Trial: 16208149
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 mg)
Trial: 2180849
Drug: Enalapril and
RxNorm normalized name: enalapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril and Hydrochlorothiazide combination (32.5 mg)
Trial: 31126121
Drug: Calcium +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium + vitamin D supplements (1500 mg/day Ca and 600 IU/day vitamin D)
Trial: 31126121
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills (Control)
Trial: 26694929
Drug: Control (C)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (C) - sham block with 2 ml normal saline
Trial: 24666144
Drug: Functional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional therapy (focused on sleep and daily lifestyle regularity)
Trial: 24666144
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (focused on emotional issues, avoiding sleep and lifestyle regularity)
Trial: 17889491
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide
Trial: 15953714
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (EPO) 10000 IU thrice weekly subcutaneously (n = 211)
Trial: 8697548
Drug: 0.5 L
RxNorm normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 L Ringer's lactate (Group 1)
Trial: 8697548
Drug: 1.0 L
RxNorm normalized name: NUTREN 1.0 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 L Ringer's lactate (Group 2)
Trial: 6609700
Drug: Piroxicam 20mg
RxNorm normalized name: PIROXICAM 20MG CAP
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam 20mg once daily
Trial: 6609700
Drug: Ibuprofen 400mg
RxNorm normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400mg three times a day
Trial: 29555497
Drug: Outpatient physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient physical therapy (PT) for 6 weeks
Trial: 28011813
Drug: 2-dose MV
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose MV
Trial: 28011813
Drug: 2-dose MV
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose MV with OPV0 in the first week of life
Trial: 28011813
Drug: 2-dose MV
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose MV with OPV0 after the first month of life
Trial: 28011813
Drug: 2-dose MV
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose MV without campaign-OPV
Trial: 28011813
Drug: 1-dose MV
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose MV with campaign-OPV before enrolment
Trial: 28011813
Drug: 2-dose MV
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose MV with campaign-OPV before enrolment
Trial: 24803100
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg simvastatin day(-1) with 75 mg clopidogrel day(-1)
Trial: 24803100
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg fluvastatin day(-1) with 75 mg clopidogrel day(-1)
Trial: 24803100
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel day(-1) alone
Trial: 24803100
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel day(-1) with simvastatin
Trial: 24803100
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel day(-1) with fluvastatin
Trial: 19276396
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 with NVBiv 30 mg/m2 on day 1 and NVBo 80 mg/m2 on day 8 every 3 weeks (arm A)
Trial: 19276396
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 and DCT 75 mg/m2 on day 1 every 3 weeks (arm B)
Trial: 12150702
Drug: Experimental therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapies involving IL-10, transforming growth factor-beta, granulocyte colony-stimulating factor, and IFN-phi
Trial: 9638985
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of behenoyl‐cytosine‐arabinoside (BHAC), daunorubicin (DNR), 6‐mercaptopurine (6‐MP) and prednisolone (PSL)
Trial: 9638985
Drug: Residual leukemic
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual leukemic cell counts of less than 300 cells/microl in the bone marrow at the end point of induction therapy
Trial: 8074068
Drug: 42 g
RxNorm normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 g fat
Trial: 8074068
Drug: 31 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 31 g fat
Trial: 29980128
Drug: Inpatient and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient and day hospital treatment
Trial: 29980128
Drug: Nonresponse at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponse at the end of treatment
Trial: 28489240
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection into the tonsillar capsule during electrical tonsillectomy
Trial: 28489240
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection during electrical tonsillectomy
Trial: 25589220
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg single dose
Trial: 25589220
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg single dose with ketoconazole 400 mg once daily